Summary
Cardinal Health Inc. (CAH) reported its second quarter fiscal year 2025 results, showing a decrease in revenue primarily due to the expiration of OptumRx contracts. Despite this revenue headwind, both GAAP and Non-GAAP operating earnings and diluted EPS saw significant year-over-year growth. This improvement was driven by enterprise-wide cost savings measures, growth in the BioPharma Solutions segment, and contributions from specialty networks and acquisitions. The company also highlighted substantial acquisitions, including ION and GI Alliance, which are expected to contribute to future growth, alongside a pending acquisition of Advanced Diabetes Supply Group. Management remains confident in the company's liquidity and ability to fund operations and future needs. Operationally, the Pharmaceutical and Specialty Solutions segment experienced a revenue decline but showed improved segment profit, driven by branded and specialty pharmaceutical products and BioPharma Solutions growth, partially offset by the OptumRx contract impact. The Global Medical Products and Distribution segment saw modest revenue and segment profit growth. The company also addressed significant cash outflows related to opioid litigation settlements, continuing its commitment to resolve these matters. Looking ahead, Cardinal Health is actively integrating recent acquisitions and expects them to positively impact future segment revenue and profit.
Financial Highlights
47 data points| Revenue | $55.26B |
| Cost of Revenue | $53.32B |
| Gross Profit | $1.94B |
| SG&A Expenses | $1.31B |
| Operating Income | $549.00M |
| Interest Expense | $35.00M |
| Net Income | $400.00M |
| Shares Outstanding (Basic) | 242.00M |
| Shares Outstanding (Diluted) | 243.00M |
Key Highlights
- 1Revenue for the quarter decreased 4% to $55.3 billion, primarily due to the OptumRx contract expiration, though branded and specialty pharmaceutical sales provided some offset.
- 2GAAP operating earnings increased 9% to $549 million, and Non-GAAP operating earnings grew 9% to $635 million, demonstrating operational efficiencies and segment growth.
- 3GAAP diluted EPS rose 10% to $1.65, while Non-GAAP diluted EPS increased 2% to $1.93, reflecting improved profitability.
- 4The company completed the acquisition of ION for $1.1 billion and announced the acquisition of GI Alliance for $2.8 billion, with a pending acquisition of Advanced Diabetes Supply Group for $1.1 billion, signaling a strategic focus on expansion.
- 5Cash and equivalents decreased to $3.8 billion from $5.1 billion, impacted by $2.0 billion in net cash used in operating activities, including $692 million for opioid litigation payments, and significant acquisition-related investments.
- 6Gross margin increased 5% to $1.9 billion, with gross margin rates improving due to a favorable product mix and increased contributions from branded and specialty pharmaceuticals, as well as BioPharma Solutions.
- 7The Pharmaceutical and Specialty Solutions segment profit increased 7% year-over-year, demonstrating resilience despite revenue challenges from contract expirations.